Skip to main content




Indonesia authorises Sinovac COVID-19 vaccine for children aged 6-11

Indonesia authorises Sinovac COVID-19 vaccine for children aged 6-11

A man receives a shot of the Sinovac vaccine for COVID-19 during a vaccination campaign at the Patriot Candrabhaga Stadium in Bekasi on the outskirts of Jakarta, Indonesia on Oct 28, 2021. (Photo: AP/Achmad Ibrahim)

JAKARTA: Indonesia has approved the Sinovac Biotech COVID-19 vaccine for children aged 6-11, its food and drug agency said on Monday (Nov 1), following the US Food and Drug Administration's approval of the Pfizer/BioNTech vaccine for younger kids.

Until Monday, Indonesia had cleared the Chinese-made Sinovac vaccine only for people aged 12 and above, of which it has the most amount in its arsenal with over 200 million doses.

Penny K Lukito, chief of the agency (BPOM), told a news conference that the approval was "pleasant news. We're sure that children's vaccination is an urgent thing, especially now that ... in-person learning has started."

The approval comes as Indonesia is two months into its trial of in-person learning. Health minister Budi Gunadi Sadikin said that COVID-19 cases found in schools during this period "are relatively low."

Siti Nadia Tarmizi, a health ministry official, said that vaccinations for children may start early next year, as it awaits further recommendation from Indonesia's paediatric association and more vaccine shots.

Chile and Cambodia have also approved the Sinovac vaccine for younger children.

Indonesia was Asia's COVID-19 epicentre in July, with the Delta variant driving up infections and deaths though both counts have plummeted.

Infections among children aged 0-18 make up for 13 per cent of total cases, government data shows.

Indonesia has vaccinated about 27 per cent of its population of 270 million.

BOOKMARK THIS: Our comprehensive coverage of the COVID-19 pandemic and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak:

Source: Reuters/ic


Also worth reading